These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16180990)
1. An interview with Anne Hermanowski-Vosatka, M.D., Ph.D. Interview by Vicki Glaser. Hermanowski-Vosatka A Assay Drug Dev Technol; 2005 Aug; 3(4):363-6. PubMed ID: 16180990 [No Abstract] [Full Text] [Related]
2. Recent advances in the discovery of 11beta-HSD1 inhibitors. Boyle CD Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567 [TBL] [Abstract][Full Text] [Related]
3. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Wang M Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818 [TBL] [Abstract][Full Text] [Related]
5. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. Odermatt A Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Su X; Vicker N; Potter BV Prog Med Chem; 2008; 46():29-130. PubMed ID: 18381124 [No Abstract] [Full Text] [Related]
7. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143 [TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome. Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111 [TBL] [Abstract][Full Text] [Related]
9. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Wake DJ; Walker BR Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174 [TBL] [Abstract][Full Text] [Related]
10. Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Mundt S; Solly K; Thieringer R; Hermanowski-Vosatka A Assay Drug Dev Technol; 2005 Aug; 3(4):367-75. PubMed ID: 16180991 [TBL] [Abstract][Full Text] [Related]
11. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Nuotio-Antar AM; Hachey DL; Hasty AH Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220 [TBL] [Abstract][Full Text] [Related]
12. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856 [TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome. Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866 [TBL] [Abstract][Full Text] [Related]
15. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Scott JS; Goldberg FW; Turnbull AV J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Yang H; Dou W; Lou J; Leng Y; Shen J Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087 [TBL] [Abstract][Full Text] [Related]
17. Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I. Valeur E; Christmann-Franck S; Lepifre F; Carniato D; Cravo D; Charon C; Bozec S; Musil D; Hillertz P; Doare L; Schmidlin F; Lecomte M; Schultz M; Roche D Bioorg Med Chem Lett; 2012 Sep; 22(18):5909-14. PubMed ID: 22901389 [TBL] [Abstract][Full Text] [Related]
18. Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children? Fürst-Recktenwald S; Dörr HG; Quinkler M; Dötsch J; Stewart PM Clin Endocrinol (Oxf); 2012 Aug; 77(2):159-68. PubMed ID: 22486586 [TBL] [Abstract][Full Text] [Related]
19. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Stimson RH; Walker BR Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731 [TBL] [Abstract][Full Text] [Related]
20. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Wang M Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]